Previous studies have shown that patients with medulloblastoma have a series of altered molecular genetic patterns such as deletion of the oncogene PTEN, p53 mutations, and abnormalities in SHH and WNT signaling pathways [19]. The gene discussed is TP53; the disease is medulloblastoma.